{"id":830191,"date":"2025-03-26T16:07:39","date_gmt":"2025-03-26T20:07:39","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/crispr-therapeutics-announces-transition-of-chief-operating-officer\/"},"modified":"2025-03-26T16:07:39","modified_gmt":"2025-03-26T20:07:39","slug":"crispr-therapeutics-announces-transition-of-chief-operating-officer","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/crispr-therapeutics-announces-transition-of-chief-operating-officer\/","title":{"rendered":"CRISPR Therapeutics Announces Transition of Chief Operating Officer"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">ZUG, Switzerland and BOSTON, March  26, 2025  (GLOBE NEWSWIRE) &#8212; CRISPR Therapeutics\u00a0(Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that its Chief Operating Officer, Julianne Bruno, will be stepping down from the Company to pursue external opportunities, effective as of April 11, 2025.<\/p>\n<p>\u201cJulie has been an invaluable member of our leadership team over the last six years. Her leadership has been instrumental in successfully advancing our hematology and oncology programs, as well as several important cross-functional initiatives to mature our operating model,\u201d said\u00a0Samarth\u00a0Kulkarni, Ph.D., Chairman and Chief Executive Officer of CRISPR Therapeutics. \u201cI want to thank her for her contributions and wish her all the best in her future endeavors and continued success.\u201d<\/p>\n<p align=\"justify\">\n        <strong>About\u00a0CRISPR Therapeutics<\/strong><br \/>\n        <br \/>Since its inception over a decade ago,\u00a0CRISPR Therapeutics\u00a0has evolved from a research-stage company advancing gene editing programs into a leader that celebrated the historic approval of the first-ever CRISPR-based therapy. The Company has a diverse portfolio of product candidates across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, cardiovascular, autoimmune, and rare diseases. In 2018,\u00a0CRISPR Therapeutics\u00a0advanced the first-ever CRISPR\/Cas9 gene-edited therapy into the clinic to investigate the treatment of sickle cell disease and transfusion-dependent beta thalassemia. Beginning in late 2023, CASGEVY<sup>\u00ae<\/sup>\u00a0(exagamglogene autotemcel [exa-cel]) was approved in several countries to treat eligible patients with either of these conditions. The Nobel Prize-winning CRISPR technology has revolutionized biomedical research and represents a powerful, clinically validated approach with the potential to create a new class of potentially transformative medicines. To accelerate and expand its efforts,\u00a0CRISPR Therapeutics\u00a0has formed strategic partnerships with leading companies including\u00a0Vertex Pharmaceuticals.\u00a0CRISPR Therapeutics AG\u00a0is headquartered in\u00a0Zug,\u00a0Switzerland, with its wholly-owned\u00a0U.S.\u00a0subsidiary,\u00a0CRISPR Therapeutics, Inc., and R&amp;D operations based in\u00a0Boston, Massachusetts\u00a0and\u00a0San Francisco,\u00a0California. To learn more, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5UPLcEKp-qT0bAFxO1OYYkw3UuqbQSc3hApKhZDSawXL4_eSBlvmPVOeqNYLlObBOLf8-5rhzYMQx76AmX0aiRAF8MXMFouHJMzN8Wod_ujtT4Z8zB8GLFKZlQeVxF-m_VjKZZmYHvJi2E69SeOusSVOzJzB-u4Z_lUfM-nhfEP5u0ksVACd3Yk3buA0CAiIjj2qF1_QHPCuP6eDsefmRF9Ft1kKlUtBCVyNpM49sA9DXTxbLXd_rAOKM0yCJGvL2lhQMsZtoMDhnYgvPY3-EQ==\" rel=\"nofollow\" target=\"_blank\">www.crisprtx.com<\/a>.<\/p>\n<p>\n        <strong>Investor Contact:<\/strong><br \/>\n        <br \/>+1-617-307-7503<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=3kYvhWjxdJmC-fbPtlR9ZesXcDszfSGfKoscbha_gqiMwPYdHOFgGZWY71tZfrzrgDChXQ_SJKBNXGSImd_oCTUZXcDqXzoiFp339a1ncjQxogiUr4_msLIp0C1i4IfrlYOO9Eo3yzHHcqzQl0SRqXNroFq2YQ5FOE43gIeUxjJusQRGiI7JVyhMZdF5HTlJOcJCIkA7fzSlBkGhDk1_sauwwos6RiKcvTTfwry8jV4=\" rel=\"nofollow\" target=\"_blank\">ir@crisprtx.com<\/a><\/p>\n<p>\n        <strong>Media Contact:<\/strong><br \/>\n        <br \/>+1-617-315-4493<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=L4Kq86mXNit2xWCsFDDg2FHUgqj_NqlmWPyeukvgpC9PKRv5uJBPdh3A1NkGI3xSReixVzSdcQxkchRJTU6BDWuWQ44F_0ZMO9Sy0MkUmM6tgss8oot1lGrOP6o1Cz2254PFDiuPIhtIMM3jztYkreNdv4Q1qorRcXL2xjpEnHvdUG6GRKbJVWj65t3TYboHpB3zly2Z8Ba4QnHxwf26uRhFKaBdpx5p1OWCq__0a-8TQQKkTOEhEuJ5ZejTdat-L3am36aGMWVFngz_GoNxrw==\" rel=\"nofollow\" target=\"_blank\">media@crisprtx.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxMTM4NyM2ODM1NTk4IzIwNDk5MTE=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/YTQ4ODFmYjgtYzM4OC00Njc3LWE2MTMtZTU1NTY0ODEwYmYyLTEwNjE0ODItMjAyNS0wMy0yNi1lbg==\/tiny\/CRISPR-Therapeutics-AG.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>ZUG, Switzerland and BOSTON, March 26, 2025 (GLOBE NEWSWIRE) &#8212; CRISPR Therapeutics\u00a0(Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that its Chief Operating Officer, Julianne Bruno, will be stepping down from the Company to pursue external opportunities, effective as of April 11, 2025. \u201cJulie has been an invaluable member of our leadership team over the last six years. Her leadership has been instrumental in successfully advancing our hematology and oncology programs, as well as several important cross-functional initiatives to mature our operating model,\u201d said\u00a0Samarth\u00a0Kulkarni, Ph.D., Chairman and Chief Executive Officer of CRISPR Therapeutics. \u201cI want to thank her for her contributions and wish her all the best in her future endeavors and &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/crispr-therapeutics-announces-transition-of-chief-operating-officer\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;CRISPR Therapeutics Announces Transition of Chief Operating Officer&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-830191","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>CRISPR Therapeutics Announces Transition of Chief Operating Officer - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/crispr-therapeutics-announces-transition-of-chief-operating-officer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CRISPR Therapeutics Announces Transition of Chief Operating Officer - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"ZUG, Switzerland and BOSTON, March 26, 2025 (GLOBE NEWSWIRE) &#8212; CRISPR Therapeutics\u00a0(Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that its Chief Operating Officer, Julianne Bruno, will be stepping down from the Company to pursue external opportunities, effective as of April 11, 2025. \u201cJulie has been an invaluable member of our leadership team over the last six years. Her leadership has been instrumental in successfully advancing our hematology and oncology programs, as well as several important cross-functional initiatives to mature our operating model,\u201d said\u00a0Samarth\u00a0Kulkarni, Ph.D., Chairman and Chief Executive Officer of CRISPR Therapeutics. \u201cI want to thank her for her contributions and wish her all the best in her future endeavors and &hellip; Continue reading &quot;CRISPR Therapeutics Announces Transition of Chief Operating Officer&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/crispr-therapeutics-announces-transition-of-chief-operating-officer\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-26T20:07:39+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxMTM4NyM2ODM1NTk4IzIwNDk5MTE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crispr-therapeutics-announces-transition-of-chief-operating-officer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crispr-therapeutics-announces-transition-of-chief-operating-officer\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"CRISPR Therapeutics Announces Transition of Chief Operating Officer\",\"datePublished\":\"2025-03-26T20:07:39+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crispr-therapeutics-announces-transition-of-chief-operating-officer\\\/\"},\"wordCount\":336,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crispr-therapeutics-announces-transition-of-chief-operating-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxMTM4NyM2ODM1NTk4IzIwNDk5MTE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crispr-therapeutics-announces-transition-of-chief-operating-officer\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crispr-therapeutics-announces-transition-of-chief-operating-officer\\\/\",\"name\":\"CRISPR Therapeutics Announces Transition of Chief Operating Officer - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crispr-therapeutics-announces-transition-of-chief-operating-officer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crispr-therapeutics-announces-transition-of-chief-operating-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxMTM4NyM2ODM1NTk4IzIwNDk5MTE=\",\"datePublished\":\"2025-03-26T20:07:39+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crispr-therapeutics-announces-transition-of-chief-operating-officer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crispr-therapeutics-announces-transition-of-chief-operating-officer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crispr-therapeutics-announces-transition-of-chief-operating-officer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxMTM4NyM2ODM1NTk4IzIwNDk5MTE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxMTM4NyM2ODM1NTk4IzIwNDk5MTE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crispr-therapeutics-announces-transition-of-chief-operating-officer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CRISPR Therapeutics Announces Transition of Chief Operating Officer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CRISPR Therapeutics Announces Transition of Chief Operating Officer - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/crispr-therapeutics-announces-transition-of-chief-operating-officer\/","og_locale":"en_US","og_type":"article","og_title":"CRISPR Therapeutics Announces Transition of Chief Operating Officer - Market Newsdesk","og_description":"ZUG, Switzerland and BOSTON, March 26, 2025 (GLOBE NEWSWIRE) &#8212; CRISPR Therapeutics\u00a0(Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that its Chief Operating Officer, Julianne Bruno, will be stepping down from the Company to pursue external opportunities, effective as of April 11, 2025. \u201cJulie has been an invaluable member of our leadership team over the last six years. Her leadership has been instrumental in successfully advancing our hematology and oncology programs, as well as several important cross-functional initiatives to mature our operating model,\u201d said\u00a0Samarth\u00a0Kulkarni, Ph.D., Chairman and Chief Executive Officer of CRISPR Therapeutics. \u201cI want to thank her for her contributions and wish her all the best in her future endeavors and &hellip; Continue reading \"CRISPR Therapeutics Announces Transition of Chief Operating Officer\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/crispr-therapeutics-announces-transition-of-chief-operating-officer\/","og_site_name":"Market Newsdesk","article_published_time":"2025-03-26T20:07:39+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxMTM4NyM2ODM1NTk4IzIwNDk5MTE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/crispr-therapeutics-announces-transition-of-chief-operating-officer\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/crispr-therapeutics-announces-transition-of-chief-operating-officer\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"CRISPR Therapeutics Announces Transition of Chief Operating Officer","datePublished":"2025-03-26T20:07:39+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/crispr-therapeutics-announces-transition-of-chief-operating-officer\/"},"wordCount":336,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/crispr-therapeutics-announces-transition-of-chief-operating-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxMTM4NyM2ODM1NTk4IzIwNDk5MTE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/crispr-therapeutics-announces-transition-of-chief-operating-officer\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/crispr-therapeutics-announces-transition-of-chief-operating-officer\/","name":"CRISPR Therapeutics Announces Transition of Chief Operating Officer - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/crispr-therapeutics-announces-transition-of-chief-operating-officer\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/crispr-therapeutics-announces-transition-of-chief-operating-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxMTM4NyM2ODM1NTk4IzIwNDk5MTE=","datePublished":"2025-03-26T20:07:39+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/crispr-therapeutics-announces-transition-of-chief-operating-officer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/crispr-therapeutics-announces-transition-of-chief-operating-officer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/crispr-therapeutics-announces-transition-of-chief-operating-officer\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxMTM4NyM2ODM1NTk4IzIwNDk5MTE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxMTM4NyM2ODM1NTk4IzIwNDk5MTE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/crispr-therapeutics-announces-transition-of-chief-operating-officer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"CRISPR Therapeutics Announces Transition of Chief Operating Officer"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/830191","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=830191"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/830191\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=830191"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=830191"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=830191"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}